RNPA1000

RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC₅₀ of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity^[1][2][3]. In Vitro: RNPA1000 displays antimicrobial activity toward Gram-positive bacteria and little or no toxicity toward human cells^[2].
RNPA1000 limits S. aureus mRNA turnover and growth. RNPA1000 also limits growth of other important Gram-positive bacterial pathogens, exhibits antimicrobial efficacy against biofilm associated S. aureus and protects against the S. aureus pathogenesis in an animal model of infection^[3].
RNPA1000 (IC50=?100-125 μM), does not affect the activity of the commercially available E. coli RNase HI, RNase A, RNase I or in-house purified S. aureus RNase J1 at any concentration tested (0-750 μM), but does mildly inhibit E. coli RNase III activity (IC50=?500-750 μM)^[3].